News Sentiment

RIGL sentiment intelligence

Rigel Pharmaceuticals Inc news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.

Chart Weekly report Factors Options RSS feed
Weighted score 52 Balanced news tone 59 relevant articles
Exchange NASDAQ United States
Sector Healthcare Market context
Industry Biotechnology Read-through group
Latest close 36.81 Week of 31 Jul 2026
Weighted tone 52/100

Balanced news tone

Market reaction Balanced read

News tone and price action are not far from neutral.

Primary event Earnings

76/100 classification confidence.

Company focus 50

directly relevant articles

Source quality 6

high-authority source matches

Trend context Trend active

+0.2% over one week, -4.9% over four weeks, trend active, and materially above fair value.

Latest direct headline Neutral

Empowered Funds LLC Takes Position in Rigel Pharmaceuticals, Inc. $RIGL

Market Reaction

Balanced read

49/100 confidence

News tone and price action are not far from neutral.

Primary event Earnings 76/100 classification
One-week reaction 0.2% Price digesting
Trend fit Trend active -4.9% over four weeks
Fair value 70.3% Materially above fair value

Sentiment Mix

Positive, neutral, negative

Weighted by relevance
Positive 12
Neutral 41
Negative 6

Relevance

Why the article matched

Direct first
Direct company coverage 50
Industry context 9
Sector context 0

Sources

Coverage mix

Publishers
simplywall.st 8
Market source 7
TradingKey 7
Stock Titan 6
TradingView 5
Seeking Alpha 4
MarketBeat 3
Quartr 3

Event Lens

What the news is about

Classified themes
Earnings 29
Market update 22
Analyst action 2
Guidance 2
Deals and strategy 2
Regulatory and legal 1
Balance sheet 1

Sentiment Trail

Score over time

50 baseline
Above 50 Neutral zone Below 50

News Tape

Relevant headlines

Showing 1-30 of 59
Simply Wall Street Direct company coverage

Rigel Pharmaceuticals (RIGL) Stock Rally Runs Into Earnings Quality Doubts

Rigel Pharmaceuticals (RIGL) saw its stock rally after its Q2 earnings release, with a 4.6% increase following a strong three-month run. The company maintained profitability with $17.3m in net income and $78.7m in total revenue, though revenue and EPS declined significantly year-

Tone
Negative 38/100
Event
Earnings
Published
06 Aug 2026 08:41
Source
Simply Wall Street
MarketBeat Direct company coverage

Rigel Pharmaceuticals Q2 2026 Earnings Call Transcript

Rigel Pharmaceuticals reported strong Q2 2026 results, with commercial revenue growing 14% year-over-year, driven by record TAVALISSE sales and REZLIDHIA growth. The company is accelerating the launch of VEPPANU, an FDA-approved breast cancer therapy, which it expects to be its l

Tone
Positive 75/100
Event
Earnings
Published
05 Aug 2026 03:11
Source
MarketBeat
Seeking Alpha Direct company coverage

Rigel Pharmaceuticals, Inc. 2026 Q2 - Results - Earnings Call Presentation (NASDAQ:RIGL)

Rigel Pharmaceuticals, Inc. (RIGL) published a slide deck in conjunction with their Q2 2026 earnings call. The company reported an EPS of $0.88, beating estimates by $0.96, and revenue of $78.70M, which also beat estimates by $23.43M despite a 22.60% year-over-year decrease. This

Tone
Positive 70/100
Event
Earnings
Published
05 Aug 2026 02:43
Source
Seeking Alpha
Market source Direct company coverage

Rigel Pharmaceuticals (RIGL) Q2 Earnings Miss Estimates

Rigel Pharmaceuticals (RIGL) reported Q2 earnings of $0.88 per share, missing the Zacks Consensus Estimate of $0.91 per share, and significantly down from $3.28 per share a year ago. Despite missing EPS estimates, the company's Q2 revenues of $78.7 million surpassed the consensus

Tone
Negative 30/100
Event
Earnings
Published
04 Aug 2026 21:11
Source
Market source
Associated Press Direct company coverage

Rigel: Q2 Earnings Snapshot

Tone
Neutral 50/100
Event
Earnings
Published
04 Aug 2026 20:08
Source
Associated Press
Stock Traders Daily Direct company coverage

(RIGL) as a Liquidity Pulse for Institutional Tactics

This article analyzes Rigel Pharmaceuticals Inc. (NASDAQ: RIGL) using AI models, highlighting weak near and mid-term sentiment but a neutral long-term outlook. It identifies an exceptional short setup with a significant risk-reward ratio and outlines specific trading strategies f

Tone
Negative 27/100
Event
Guidance
Published
04 Aug 2026 19:11
Source
Stock Traders Daily
TradingKey Direct company coverage

Rigel Pharmaceuticals Inc (RIGL) Risk Assessment: Volatility, Financial Risk & Investment Risk

This article provides a risk assessment for Rigel Pharmaceuticals Inc (RIGL), noting its current risk score of 4.47 and ranking it 86th out of 155 in the Pharmaceuticals industry. It highlights the company's beta of 1.19, indicating higher volatility compared to the S&P 500 index

Tone
Neutral 50/100
Event
Market update
Published
30 Jul 2026 05:39
Source
TradingKey
TradingView Direct company coverage

Rigel Announces Conference Call and Webcast to Report Second Quarter 2026 Financial Results

Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) announced it will report its second quarter 2026 financial results on Tuesday, August 4, 2026, after market close. Following the announcement, senior management will host a live conference call and webcast at 4:30 p.m. Eastern Time to di

Tone
Neutral 50/100
Event
Earnings
Published
29 Jul 2026 05:10
Source
TradingView
TradingKey Direct company coverage

Rigel Pharmaceuticals Inc (RIGL) Valuation: PE, PB & Fair Value Analysis

This article provides a valuation analysis of Rigel Pharmaceuticals Inc (RIGL), highlighting its current valuation score and P/E ratio. It notes that the company's P/E ratio is 1.90, significantly below its recent high and above its recent low. The analysis also indicates that re

Tone
Neutral 50/100
Event
Market update
Published
29 Jul 2026 03:41
Source
TradingKey
Stock Titan Direct company coverage

Rigel schedules a live webcast for its Aug. 4 business update

Rigel Pharmaceuticals (Nasdaq: RIGL) announced it will report its second quarter 2026 financial results on Tuesday, August 4, 2026, after market close. A live conference call and webcast will follow at 4:30 p.m. ET, led by senior management, to discuss the results and provide a b

Tone
Neutral 50/100
Event
Earnings
Published
28 Jul 2026 12:11
Source
Stock Titan
TradingKey Direct company coverage

RIGL|Rigel Pharmaceuticals Inc|Price:37.126|Chg%:-0.264

This article provides a comprehensive stock analysis of Rigel Pharmaceuticals Inc (RIGL) by TradingKey. It highlights the company's strong fundamentals and high growth potential, despite its stock trading sideways recently. The analysis also covers the company's valuation, instit

Tone
Positive 71/100
Event
Market update
Published
28 Jul 2026 03:39
Source
TradingKey
TradingKey Direct company coverage

Rigel Pharmaceuticals Inc (RIGL) Shareholder Structure: Major Shareholders & Institutional Holdings

This article details the shareholder structure of Rigel Pharmaceuticals Inc (RIGL), highlighting major institutional investors and their holdings. It breaks down shareholders by type and reports on changes in institutional ownership over several quarters. The data provides insigh

Tone
Neutral 50/100
Event
Market update
Published
27 Jul 2026 19:11
Source
TradingKey
TradingView Direct company coverage

Rigel Pharmaceuticals, Inc. Revenue Breakdown – NASDAQ:RIGL

Rigel Pharmaceuticals, Inc. (NASDAQ: RIGL) generated $294.28 million in revenue last year, primarily from its Novel Therapies segment. This is an increase from $179.28 million the previous year. The United States was the company's largest contributor to revenue.

Tone
Neutral 50/100
Event
Earnings
Published
27 Jul 2026 15:11
Source
TradingView
TradingKey Direct company coverage

Rigel Pharmaceuticals Inc (RIGL) Dividends & Stock Splits: Historical Payouts and Event Timeline

This article provides historical data on dividends and stock splits for Rigel Pharmaceuticals Inc (RIGL). It indicates that the company has not distributed any dividends in the past five years. The report also details multiple merger-related stock splits with a 10:1 ratio that oc

Tone
Neutral 50/100
Event
Deals and strategy
Published
27 Jul 2026 02:09
Source
TradingKey
TradingKey Direct company coverage

Rigel Pharmaceuticals Inc (RIGL) Income Statement

This article provides the quarterly and annual income statements for Rigel Pharmaceuticals Inc (RIGL), offering detailed financial data such as total revenue, cost of revenue, operating expenses, and net income across multiple fiscal years and quarters. It also includes frequentl

Tone
Positive 64/100
Event
Earnings
Published
26 Jul 2026 04:20
Source
TradingKey
TradingView Direct company coverage

Rigel Pharmaceuticals, Inc. Revenue Breakdown – MUN:RI2

Rigel Pharmaceuticals, Inc. (MUN:RI2) generated 250.56 million EUR last year, a significant increase from 173.18 million EUR in the previous year. This revenue primarily stemmed from its Novel Therapies segment, with the United States being the largest contributing region. The co

Tone
Positive 65/100
Event
Earnings
Published
25 Jul 2026 08:12
Source
TradingView
TradingKey Direct company coverage

Rigel Pharmaceuticals Inc (RIGL) Financial Health: Profitability & Balance Sheet Analysis

Rigel Pharmaceuticals Inc (RIGL) has a robust financial health score of 8.03, ranking 86th out of 155 in the Pharmaceuticals industry, indicating high operating efficiency. The company reported a 10.28% year-over-year revenue increase to $58.82 million and a 24.39% year-over-year

Tone
Positive 72/100
Event
Earnings
Published
24 Jul 2026 14:40
Source
TradingKey
Stock Traders Daily Direct company coverage

(RIGL) Risk Channels and Responsive Allocation

Rigel Pharmaceuticals Inc. (NASDAQ: RIGL) is presenting a weak near-term sentiment, although an exceptional 81.5:1 risk-reward setup is noted, targeting a 24.2% gain against 0.3% risk. AI models have developed three trading strategies: Position Trading (LONG), Momentum Breakout (

Tone
Negative 38/100
Event
Market update
Published
23 Jul 2026 14:27
Source
Stock Traders Daily